Objective: To examine the prevalence of BRAF mutation among thyroid cancer histologic
subtypes and determine the association of BRAF mutation with indicators of poor prognosis …

Purpose: Oncogenic conversion of BRAF occurs in∼ 44% of papillary thyroid carcinomas
and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is …

Context: The role of the T1799A BRAF mutation in lymph node metastasis of papillary
thyroid cancer (PTC) is not clear. Objective: Our objective was to explore the relationship …

BRAF gene mutations have been frequently detected in papillary thyroid carcinoma (PTC).
Moreover, there is a close association between the type of mutation and the PTC histotype …

The B-type Raf kinase (BRAF) protein is a serine/threonine kinase that has an important role
in cellular proliferation, differentiation, and programmed cell death. The BRAF gene has …

Anaplastic thyroid carcinoma is a highly aggressive neoplasm. Affected patients typically
present with advanced disease where there is little hope for cure using conventional …

Thyroid papillary cancers (PTCs) are associated with activating mutations of genes coding
for RET or TRK tyrosine kinase receptors, as well as of RAS genes. Activating mutations of …

Activating mutations in the gene encoding BRAF are the most commonly identified
oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have …

Background: The mutated BRAF V600E protein has been specifically detected in papillary
thyroid carcinomas (PTCs) using immunohistochemical (IHC) analysis. The clonal origin of …

Background The objective of this study is to perform a meta-analysis to evaluate the
associations between the BRAF V600E mutation status and aggressive clinicopathological …